| Michael C Chen, MD | |
|
1830 Bethel Rd Ste C, Columbus, OH 43220-1809 | |
| (614) 754-8781 | |
| (614) 754-8924 |
| Full Name | Michael C Chen |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 21 Years |
| Location | 1830 Bethel Rd Ste C, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114131042 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35089664 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Forefront Dermatology | 3779471701 | 474 |
News Archive
The micro RNA miR-22 has long been known for its ability to suppress cancer. However, questions remain about how it achieves this feat. For example, which molecules are regulating miR-22, and which are miR22 targets?
The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.
Tufts University and Tufts Medical Center today announced that the National Institutes of Health has named the Tufts Clinical and Translational Science Institute (CTSI) a recipient of the 2013 Clinical and Translational Science Awards (CTSA).
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.
› Verified 5 days ago
| Entity Name | Skin Cancer And Dermatology Of Columbus, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265759013 PECOS PAC ID: 5092848168 Enrollment ID: O20100727000738 |
News Archive
The micro RNA miR-22 has long been known for its ability to suppress cancer. However, questions remain about how it achieves this feat. For example, which molecules are regulating miR-22, and which are miR22 targets?
The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.
Tufts University and Tufts Medical Center today announced that the National Institutes of Health has named the Tufts Clinical and Translational Science Institute (CTSI) a recipient of the 2013 Clinical and Translational Science Awards (CTSA).
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.
› Verified 5 days ago
| Entity Name | Forefront Dermatology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891183059 PECOS PAC ID: 3779471701 Enrollment ID: O20150402000858 |
News Archive
The micro RNA miR-22 has long been known for its ability to suppress cancer. However, questions remain about how it achieves this feat. For example, which molecules are regulating miR-22, and which are miR22 targets?
The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.
Tufts University and Tufts Medical Center today announced that the National Institutes of Health has named the Tufts Clinical and Translational Science Institute (CTSI) a recipient of the 2013 Clinical and Translational Science Awards (CTSA).
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael C Chen, MD 801 York St, Manitowoc, WI 54220-4630 Ph: (920) 663-9008 | Michael C Chen, MD 1830 Bethel Rd Ste C, Columbus, OH 43220-1809 Ph: (614) 754-8781 |
News Archive
The micro RNA miR-22 has long been known for its ability to suppress cancer. However, questions remain about how it achieves this feat. For example, which molecules are regulating miR-22, and which are miR22 targets?
The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.
Tufts University and Tufts Medical Center today announced that the National Institutes of Health has named the Tufts Clinical and Translational Science Institute (CTSI) a recipient of the 2013 Clinical and Translational Science Awards (CTSA).
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.
› Verified 5 days ago
Benjamin Harris Kaffenberger, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1328 Dublin Rd Ste 100, Columbus, OH 43215 Phone: 614-293-1707 Fax: 614-293-1716 | |
Dr. Alecia Marie Blaszczak, MD, PHD Dermatology Medicare: Medicare Enrolled Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-688-4497 | |
Joy L Mosser-goldfarb, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 555 S 18th St, Columbus, OH 43205 Phone: 614-722-6200 | |
Mary Jo Kendrick, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3555 Olentangy River Rd, Suite 4000, Columbus, OH 43214 Phone: 614-268-2748 Fax: 614-263-3376 | |
Clem Ryan Kirkland, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3555 Olentangy River Rd, Suite 4000, Columbus, OH 43214 Phone: 614-268-2748 Fax: 614-263-3376 | |
Stephanie K. Fabbro, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4300 Clime Rd Ste 100, Columbus, OH 43228 Phone: 614-887-7723 Fax: 614-639-8003 |